Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;80(5):859-868.
doi: 10.1111/his.14622. Epub 2022 Mar 3.

Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?

M Sasaki  1 , Y Sato  1 , Y Nakanuma  2
Affiliations

Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?

M Sasaki et al. Histopathology. 2022 Apr.

Abstract

Background and aims: The type IV intermediate filament, nestin, may be a candidate diagnostic marker for combined hepatocellular-cholangiocarcinoma (cHCC-CCA). Therefore, the significance of nestin as a diagnostic marker for cHCC-CCA categorized by the World Health Organization (WHO) 2019 classification and its relationship with clinicopathological features were examined in the present study.

Methods and results: Nestin expression was immunohistochemically assessed in the liver sections from 75 patients with cHCC-CCA, 22 with small duct-type intrahepatic cholangiocarcinoma (iCCA), 20 with large duct-type iCCA and 35 with hepatocellular carcinoma (HCC). Nestin expression and its relationship with clinicopathological features and genetic alterations were investigated in cHCC-CCA. Nestin expression was detected in significantly more patients with cHCC-CCA (66.7%) than in those with large duct-type iCCA (5%) (P < 0.01), HCC (2.9%) (P < 0.01) and small duct-type iCCA (40.9%) (P < 0.05). Nestin expression was partly associated with neural cell adhesion molecule (NCAM) and vimentin expression. Nestin expression was also observed in significantly more patients with small duct-type iCCA than in those with large duct-type iCCA and HCC (P < 0.01). Nestin-positive cHCC-CCA was characterized by a smaller tumour size, the more frequent presence of cholangiolocellular carcinoma (CLC) components, a higher rate of p53 overexpression and a higher rate of multiple genetic alterations (P < 0.05). Furthermore, p53 overexpression was associated with a higher histological grade and multiple genetic alterations (P < 0.05) in nestin-positive cHCC-CCA.

Conclusion: Nestin may be a useful diagnostic marker for a specific subgroup of cHCC-CCA and small duct-type iCCA associated with CLC components, p53 mutations and multiple genetic alterations, which are related to stemness and multipotent differentiation.

Keywords: combined hepatocellular and cholangiocarcinoma; intrahepatic cholangiocarcinoma; nestin; p53; small duct type.

PubMed Disclaimer

References

    1. Sempoux C, Kakar S, Kondo F, Schirmacher P. Combined hepatocellular-cholangiocarcinoma and undifferentiated primary liver carcinoma. In the WHO Classification of Tumours Editorial Board ed. WHO classification of tumours. Digestive system tumours. Lyon: IARC, 2019; 260-262.
    1. Beaufrere A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: an update. J. Hepatol. 2021; 74; 1212-1224.
    1. Brunt E, Aishima S, Clavien PA et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology 2018; 68; 113-126.
    1. Xue R, Chen L, Zhang C et al. Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell 2019; 35; 932-947 e938.
    1. Bernal A, Arranz L. Nestin-expressing progenitor cells: function, identity and therapeutic implications. Cell. Mol. Life Sci. 2018; 75; 2177-2195.

MeSH terms